
Moderna Inc (NASDAQ:MRNA) has dosed the first participant in the Phase 2 study of its omicron-specific bivalent booster candidate (mRNA-1273.214).
The vaccine candidate combines Moderna's omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273).